Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLSI Greenwich LifeSciences	$11.59 -5.8%	$9.73	$8.06 ▼ $17.00	$154.96M	1.63	46,335 shs	154,544 shs
TSHA Taysha Gene Therapies	$2.57 -0.8%	$2.57	$1.05 ▼ $3.31	$551.68M	0.97	2.95 million shs	3.38 million shs
TYRA Tyra Biosciences	$10.39 -4.3%	$9.89	$6.42 ▼ $29.60	$551.61M	1.07	291,196 shs	103,996 shs
ZVRA Zevra Therapeutics	$12.07 -4.7%	$9.45	$5.45 ▼ $13.16	$659.99M	1.97	736,113 shs	1.20 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLSI Greenwich LifeSciences	+9.92%	+9.63%	+36.21%	+37.43%	-24.21%
TSHA Taysha Gene Therapies	+1.97%	+1.57%	+1.57%	+108.87%	+13.10%
TYRA Tyra Biosciences	-0.55%	+6.05%	+13.24%	+21.75%	-45.97%
ZVRA Zevra Therapeutics	+2.76%	+5.32%	+43.70%	+77.06%	+92.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLSI Greenwich LifeSciences	2.1662 of 5 stars	3.5	0.0	3.3	3.3	0.0
TSHA Taysha Gene Therapies	4.0299 of 5 stars	4.5	5.0	2.6	3.3	0.0
TYRA Tyra Biosciences	3.1205 of 5 stars	3.5	5.0	1.5	3.3	0.0
ZVRA Zevra Therapeutics	3.1021 of 5 stars	3.6	5.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	236.50% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.17	217.77% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	196.76% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.71	96.47% Upside

Current Analyst Ratings Breakdown

Latest GLSI, ZVRA, TYRA, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
TSHA Taysha Gene Therapies	$8.33M	66.23	N/A	N/A	$0.35 per share	7.34
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A
ZVRA Zevra Therapeutics	$23.61M	27.95	N/A	N/A	$0.74 per share	16.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/13/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	60.35	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest GLSI, ZVRA, TYRA, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GLSI Greenwich LifeSciences	-$0.24	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ZVRA Zevra Therapeutics	$0.65	N/A	N/A	N/A	$22.49 million	N/A
8/11/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	N/A	N/A	N/A	$1.61 million	N/A
8/6/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLSI Greenwich LifeSciences	N/A	1.91	1.91
TSHA Taysha Gene Therapies	0.77	5.35	5.35
TYRA Tyra Biosciences	N/A	22.78	22.78
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLSI Greenwich LifeSciences	4.16%
TSHA Taysha Gene Therapies	77.70%
TYRA Tyra Biosciences	84.14%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
GLSI Greenwich LifeSciences	51.67%
TSHA Taysha Gene Therapies	3.78%
TYRA Tyra Biosciences	15.20%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

GLSI, ZVRA, TYRA, and TSHA Headlines

Recent News About These Companies

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

July 18 at 7:30 AM | globenewswire.com

Q2 EPS Forecast for Zevra Therapeutics Boosted by Analyst

July 18 at 2:13 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.

July 17 at 9:39 AM | marketbeat.com

William Blair Issues Optimistic Forecast for ZVRA Earnings

July 17 at 2:25 AM | americanbankingnews.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...

July 16 at 4:53 PM | finanznachrichten.de

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice

July 16 at 1:01 PM | zacks.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16 at 10:05 AM | zacks.com

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

July 16 at 8:13 AM | globenewswire.com

Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C

July 16 at 7:52 AM | quiverquant.comQ

Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?

July 16 at 6:20 AM | marketbeat.com

Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst

July 16 at 6:02 AM | marketbeat.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 12:40 PM | finance.yahoo.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

July 15 at 10:56 AM | zacks.com

Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)

July 15 at 9:50 AM | zacks.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by Brokerages

July 15 at 2:03 AM | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from Analysts

July 15 at 2:29 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Raised to Strong-Buy at Wall Street Zen

July 14, 2025 | americanbankingnews.com

Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings

July 14, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00

July 13, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen

July 12, 2025 | marketbeat.com

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

July 11, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI, ZVRA, TYRA, and TSHA Company Descriptions

Greenwich LifeSciences NASDAQ:GLSI

$11.59 -0.71 (-5.77%)

Closing price 04:00 PM Eastern

Extended Trading

$11.62 +0.03 (+0.22%)

As of 04:16 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Taysha Gene Therapies NASDAQ:TSHA

$2.57 -0.02 (-0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 0.00 (-0.19%)

As of 04:04 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Tyra Biosciences NASDAQ:TYRA

$10.39 -0.47 (-4.33%)

Closing price 04:00 PM Eastern

Extended Trading

$10.40 +0.00 (+0.05%)

As of 04:04 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Zevra Therapeutics NASDAQ:ZVRA

$12.07 -0.59 (-4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$12.28 +0.21 (+1.74%)

As of 04:40 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time